CHRS Stock Coherus Oncology (CHRS, $1.31) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 26, 2025

GET DAILY SIGNALS

Get AI intraday signals

CHRS - Coherus Oncology Inc

MACD signal

View

Odds of UP Trend

Price: $1.31

Daily change: +$0.03 (+2.34%)

Daily volume: 972.8K

Capitalization: $157.7M

Industry: Biotechnology

This is a Bullish indicator signaling CHRS's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 48 similar cases where CHRS's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

CHRS's RSI Oscillator ascends from oversold territory

The RSI Oscillator for CHRS moved out of oversold territory on November 21, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In of the 33 cases the stock moved higher. This puts the odds of a move higher at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CHRS just turned positive on November 26, 2025. Looking at past instances where CHRS's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on November 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CHRS moved below its 50-day moving average on November 06, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CHRS crossed bearishly below the 50-day moving average on November 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CHRS entered a downward trend on November 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.797) is normal, around the industry mean (27.349). P/E Ratio (2.373) is within average values for comparable stocks, (52.390). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.898). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.546) is also within normal values, averaging (331.774).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.